Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report

Hepatocellular carcinoma (HCC) is a tumor with a high degree of malignancy. Patients have poor outcomes and short survival times, especially after progression to first-line systemic therapy. Regorafenib is the standard second-line treatment for HCC, but there is no conclusive evidence that regorafen...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in oncology 2023, Vol.13, p.1256137-1256137
Hauptverfasser:	Wan, Yanzhi, Zhu, Hong
Format:	Report
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!